OCTOBER 7TH 2020: Future of Medicine


You will meet four scientists presenting their latest research. There will be Q&A and the chance to meet with the scientists after the event.

Due to Covid-19 the number of participants are limited. First come, first served. Please register today by email to Astrid




08:00-08:30: Registration and breakfast


08:30-08:35: Opening by Tobias Dahl, SINTEF /UiO


08:35-08:50: Frøydis Sved Skottvoll, UiO: Mini-organs: the future for developing new and more personalized medicine

08:50-09:05: Ørjan Grøttem Martinsen, UiO: Smart sensor for low blood sugar


09:20-09:35: Ole Christian Lingjærde, UiO and Mads H. Haugen, OUH:
A molecular biomarker predicting treatment response in breast cancer

10:00: Finish





Frøydis Skottvoll, Universitetet i Oslo 

Frøydis Sved Skottvoll
Ph.D. fellow, research group for Bioanalytical Chemistry, University of Oslo.

Mini-organs: the future for developing new and more personalized medicine
Cells and animal testing are poor to predict human responses to various medicine. We are growing mini-organs in the laboratory and use mass spectrometry to test how mini-organs respond to medicine compared to humans. As the mini-organs can be grown from patient stem cells, the mini-organs are predicted to become the perfect fit for developing personalized medicine and tailor patient treatment. Read about Skottvoll's research in TU.



Ørjan Grøttem Martinsen

Ørjan Grøttem Martinsen, Professor, UiO, Department of Physics:

Smart sensor for low blood sugar
Hypoglycemia during sleep is a problem and a source of worry in diabetes. Although continuous glucose monitoring is becoming quite common in most industrial countries, the equipment is still expensive and some patients may prefer a simple solution, which also is non-invasive. We are developing a sensor based on a combination of physiological sensors that can detect falling blood sugar levels during the night and give a warning signal if the levels are going outside the safe range. The sensor can be worn as a smart watch on the wrist combined with one or more small patches on other body parts.


Mads H. Haugen, OUH

Mads H. Haugen, Scientist & project leader, Dept. of Tumor Biology - Institute for Cancer Research, Oslo University Hospital - together with:

Ole Christian Lingjærde, UiO

Ole Christian Lingjærde Professor, Centre for Bioinformatics, UiO; Dept of Cancer Genetics - Institute for Cancer Research, Oslo University Hospital:

A molecular biomarker predicting treatment response in breast cancer
Numerous cancer drugs are not in use today, because we don't know how to determine beforehand which patients would benefit from the drug. There is a great push towards developing better biomarkers to solve this issue. Through use of machine learning on clinical and molecular data from a Norwegian clinical trial, we have developed a molecular predictor that determines with good precision which patients will respond to a specific combination of drugs. To accomplish translation of our results into real benefit for patients we are currently evaluating a platform suitable for assessment of molecular signatures in routine pathology.

Our approach can potentially be used to develop companion diagnostics for a variety of drugs, which is becoming increasingly important for high cost treatments.



The meetings are organized by University of Oslo and Oslo Science Park, and is held in Forskningsparken – Oslo Science Park. Please register here.